1. Efficace, F., Bottomley, A., Osoba, D., Gotay, C., Flechtner, H., D’haese, S., Zurlo, A.: Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials—does HRQOL evaluation in prostate cancer research inform clinical decision making? J. Clin. Oncol. 21(18), 3502–3511 (2003)
2. Fayers, P.M., Aaronson, N.K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., on behalf of the EORTC Quality of Life Group: The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer (EORTC), Brussels (2001)
3. Gotay, C.C., Kawamoto, C.T., Bottomley, A., Efficace, F.: The prognostic significance of patient-reported outcomes in cancer clinical trials. J. Clin. Oncol. 26(8), 1355–1363 (2008)
4. Therasse, P., Mauriac, L., Welnicka-Jaskiewicz, M., Bruning, P., Cufer, T., Bonnefoi, H., Tomiak, E., Pritchard, K.I., Hamilton, A., Piccart, M.J.: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-Intensified epirubicin and cyclophosphamide–filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J. Clin. Oncol. 21(5), 843–850 (2003)
5. EQ-5D Value sets: inventory, comparative review and user guide. In: Szende, A., Oppe, M., Devlin, N. (Eds.) EuroQol Group Monographs. Springer, Dordrecht (2007), ISBN 978-1402055102